GSK/Xenoport’s Sustained-Release Restless Legs Drug Shows Efficacy
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Data from a pivotal study presented at the American Academy of Neurology meeting April 17, evaluating GlaxoSmithKline/Xenoport's sustained-release restless legs syndrome drug XP13512, added further evidence to support its safety and efficacy
You may also be interested in...
Restless Leg Syndrome Market Prepares To Move As GSK, UCB Advance Drugs
UCB could bring the first competitor to GlaxoSmithKline's Requip (ropinirole) for restless leg syndrome to market later this year after submitting an sNDA for Neupro (rotigotine) for RLS
With One Launch Under Way, SpringWorks Ramps Up For A Second
The company initiated a rolling submission with the US FDA for mirdametinib, a MEK inhibitor that is poised to be its second commercial product for a rare disease.
Mural Oncology Primed For IL-2 Readouts Next Year
The company, which Alkermes spun out last year, is now positioned as a pure-play oncology specialist with a focus on cytokines.